Skip to content
  • Escaping big pharma’s pricing with patent-free drugs

    The New York Times - 07/18/2017

    But clearly there’s room for more nonprofit drug companies. “D.N.D.I.’s success is ample proof that the model of nonprofit, open-source research and development is a viable alternative to exclusive reliance on patent and data monopolies,” said Brook Baker, a professor at Northeastern University School of Law who studies pharmaceutical development issues. Recent reports on the crisis of access to medicines by the United Nations and the British medical journal The Lancet single out D.N.D.I. as evidence that different approaches to research and development can provide improved efficiency and affordability.

  • Cookies on Northeastern sites

    This website uses cookies and similar technologies to understand your use of our website and give you a better experience. By continuing to use the site or closing this banner without changing your cookie settings, you agree to our use of cookies and other technologies. To find out more about our use of cookies and how to change your settings, please go to our Privacy Statement.